Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

BJU International

Volumn 114, Issue 4, 2014, Pages 608-616

  Martínez Piñeiro, Luis ^a   Schalken, Jack A ^b   Cabri, Patrick ^c   Maisonobe, Pascal ^c   De La Taille, Alexandre ^d  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c IPSEN   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

advanced prostate cancer; disease severity; GnRH agonist; PCA3; TMPRSS2 ERG

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ONCOPROTEIN; PROSTATE CANCER ANTIGEN 3, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; AGING; ANDROGEN DEPRIVATION THERAPY; ARTICLE; DRUG RESPONSE; DRUG SAFETY; FUSION GENE; GLEASON SCORE; HOT FLUSH; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; SINGLE DRUG DOSE; TMPRSS2 ERG GENE; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TRIPTORELIN PAMOATE;

EID: 84908131141     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12542     Document Type: Article

References (34)

1. Denham JW, Steigler A, Wilcox C, et al. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 2009; 115: 4477-4487
2. Sartor O,. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies. J La State Med Soc 2008; 160: 99-100
3. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-16
4. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-1095
5. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-1088
6. Crawford ED, Rove KO, Trabulsi EJ, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 2012; 188: 1726-1731
7. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804-1810
8. Ploussard G, Durand X, Xylinas E, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 422-429
9. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975-1979
10. van Poppel H, Haese A, Graefen M, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012; 109: 360-366
11. Chun FK, de la Taille A, van Poppel H, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009; 56: 659-667
12. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100: 1603-1607
13. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68: 1215-1222
14. Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10-16
15. Augustin H, Mayrhofer K, Pummer K, Mannweiler S,. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate 2012; 73: 203-210
16. Auprich M, Chun FK, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96-105
17. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009; 56: 275-286
18. Rostad K, Hellwinkel OJ, Haukaas SA, et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009; 117: 575-582
19. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA,. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13: 5103-5108
20. Salagierski M, Schalken JA,. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 2012; 187: 795-801
21. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3: 94ra72
22. Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O,. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 2013; 73: 242-249
23. Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013; 19: 2442-2450
24. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA,. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. Prostate 2009; 69: 1624-1634
25. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed November 2013
26. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-1592
27. Robert G, Jannink S, Smit F, et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate 2012; 73: 113-120
28. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-752
29. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-535
30. Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK,. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol 2011; 29: 683-688
31. Jost M, Day JR, Slaughter R, et al. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mole Can. 2010; 9: 174
32. Wolff JM, Ittel T, Borchers H, Brauers A, Jakse G,. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate. Urol Int 1998; 61: 12-16
33. Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012; 30: 607-613
34. Lundstrom EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig 2009; 29: 757-765